Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

937
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
937
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

666
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
666
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

335
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
335
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

291
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
291
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

738
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
738

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiorenal Disease Pathways and Treatment of Patients With Comorbid Heart Failure and Chronic Kidney Disease.

JACC. Heart failure·2026
Same author

Valvular Heart Disease in Heart Failure with Preserved Ejection Fraction.

Cardiac failure review·2026
Same author

A Contemporary Perspective on Acute Decompensated Heart Failure Classification: A State-of-the-art Review from an International Expert Group.

Cardiac failure review·2026
Same author

Left ventricular non-compaction in heart failure: contemporary perspective on diagnostic challenges and treatment opportunities.

Heart failure reviews·2026
Same author

Longitudinal loop diuretic use in patients with HFrEF initiated with sodium-glucose cotransporter 2 inhibitors.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Prevalence and prognostic role of untreated moderate-to-severe tricuspid regurgitation: a systematic review and meta-analysis.

European journal of heart failure·2026
Same journal

Severe tricuspid regurgitation is a congestion-driven cardiorenal disease: A longitudinal study defining a right heart failure phenotype.

International journal of cardiology·2026
Same journal

Applicability of ischemic heart disease clinical practice guidelines in low- and middle-income countries.

International journal of cardiology·2026
Same journal

Effectiveness of a new diagnostic algorithm for the diagnosis of unexplained syncope in patients with hypertrophic cardiomyopathy.

International journal of cardiology·2026
Same journal

The predictive role of the FIB-4 index in identifying arrhythmic risk among patients with nonischemic dilated cardiomyopathy.

International journal of cardiology·2026
Same journal

Beyond arrhythmias: Exploring heart failure in arrhythmogenic cardiomyopathy.

International journal of cardiology·2026
Same journal

Corrigendum to "First-in-human study of the K-Clip™ transcatheter annular repair system for severe functional tricuspid regurgitation" [International Journal of Cardiology 390(2023) / IJCA 131174].

International journal of cardiology·2026
See all related articles

Related Experiment Video

Updated: Mar 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Reply to: Ezetimibe: A real effect?

Gianluigi Savarese1, Pasquale Perrone-Filardi1

  • 1Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.

International Journal of Cardiology
|February 15, 2016
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.9K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K

Related Experiment Videos

Last Updated: Mar 25, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

30.9K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K